Cardiovascular Disease Incidence and Risk Mitigation in Patients with Locally Advanced or Metastatic Prostate Cancer on ADT : Episode 16

Video

March 3, 2023

Considerations For ADT Selection And Patient Education on Treatment-Related AEs

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Cardiovascular Disease Risk in Men with Prostate Cancer

EP: 2.Examining the Data From Key Clinical Trials, and Practical Strategies

EP: 3.Strategies for Mitigating Cardiovascular Risk

EP: 4.Summary and Case Study

EP: 5.A Medical Oncologist Reflects on a Typical Prostate Cancer Patient

EP: 6.A Urologist Reflects on a Typical Prostate Cancer Patient

EP: 7.A Cardiologist Reflects on a Typical Prostate Cancer Patient

EP: 8.Practice-Related And Provider-Patient Communication Strategies For Prostate Cancer Care

EP: 9.A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 10.A Medical Oncologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 11.Typical Examinations And Tests For Cardiovascular Risk Assessment in a Cardiology Practice

EP: 12.Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice

EP: 13.A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation

EP: 14.A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation

EP: 15.Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

Now Viewing

EP: 16.Considerations For ADT Selection And Patient Education on Treatment-Related AEs

EP: 17.A Urologist’s Approach to Followup For Patients on ADT And Practice Communication Strategies

EP: 18.A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

EP: 19.A Urologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

EP: 20.A Cardiologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

January 2023 AbbVie Inc. Company Confidential

Related Content

May 21st 2025

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

Hannah Clarke

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 20th 2025

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Hannah Clarke

The phase 3 study design will now be submitted for final review by the agency.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke

Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

Prostate Cancer

Cardiovascular Disease Incidence and Risk Mitigation in Patients with Locally Advanced or Metastatic Prostate Cancer on ADT

May 21st 2025

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

Hannah Clarke

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 20th 2025

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Hannah Clarke

The phase 3 study design will now be submitted for final review by the agency.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke

Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.